Overview

Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson's Disease

Status:
Active, not recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, open-label study with an active standard-of-care comparator (penicillamine)
Phase:
Phase 3
Details
Lead Sponsor:
GMP-Orphan SAS
Orphalan
Treatments:
Penicillamine
Trientine